European DataWarehouse and Zenith Global present new report: "European Non-Performing Loans: Evolution & Future Prospects"
14.10.2024 13:45:00 CEST | Business Wire | Press release
European DataWarehouse (EDW), in collaboration with Zenith Global S.p.A., has published a new report titled "European Non-Performing Loans: Evolution & Future Prospects."
The report provides a detailed analysis of the non-performing loan (NPL) market in Europe, with a particular focus on Italy and Greece, highlighting key trends, regulatory developments, and future prospects.
This report explores the evolution of the NPL market, where regulatory measures such as GACS (Garanzia Cartolarizzazione Sofferenze) in Italy and HAPS (Hellenic Asset Protection Scheme) in Greece have been implemented to facilitate NPL securitisations.
With regard to Italy, significant efforts have been made to transfer NPLs from banks to investors, thereby improving banks' capital ratios, aided by government guarantees. However, over €300 billion in non-performing exposures (NPEs) remain, which could fuel a substantial secondary market in the future, especially following regulatory changes that improve the effectiveness of distressed debt purchases. Stage 2 loans on banks’ balance sheets amount to more than €200 billion, bringing the total value of loans under review to over €500 billion.
As the NPL market evolves, there is an increasing need to improve transparency and standardise data disclosure to stimulate market transactions. The report offers an in-depth analysis of the data collection templates prepared by the European Banking Authority (EBA) and their impact on the efficiency of NPL portfolio transactions.
Dr Christian Thun, CEO of European DataWarehouse, stated: "The report highlights the significant progress made in the European NPL market over the past decade. The introduction of the EBA templates for NPL transactions is a crucial step towards increasing transparency, but more collaboration is needed to unlock the full potential of the secondary market. By improving data quality and consistency, and promoting cooperation among market participants, we can help shape a more resilient European financial system."
The report also explores the implementation of the European Commission’s 2017 Action Plan, which laid the foundation for the current regulatory framework, and analyses the Secondary Market Directive and national implementing laws, assessing how these measures will foster a more efficient market. A key issue is ensuring transparency by developing a central, consolidated solution for managing NPLs, combining data storage, creditor coordination, and transaction management to improve data quality and expand market participation.
Umberto Rasori, CEO of Zenith Global S.p.A., commented: "Zenith Global is the technical partner for this project, thanks to our extensive experience in the NPL market through the numerous securitisations we have carried out over more than 25 years. Greater transparency and compliance with European standards are key to making markets more resilient and facilitating transactions."
For more information or to access a copy of the report, click here. Interested parties must agree to the Conditions of Access and provide contact details to download the report.
About European DataWarehouse
Founded in 2012 as part of the European Central Bank's (ECB) implementation of the Asset-Backed Securities (ABS) Loan-level initiative, EDW is the first centralised data repository in Europe for the collection, validation, and download of standardised loan-level data for public and private European securitisations.
EDW currently hosts loan-level data and related documentation for over 1,500 securitisations (both public and private, STS and non-STS, as well as those subject to national and European securitisation laws). Additionally, EDW manages pools of additional credit claims and other performing and non-performing private portfolios belonging to various financial institutions across Europe, including the UK. Originators, issuers, arrangers, and servicers upload exposure information and the corresponding documentation to EDW, while data users, including institutional investors, data providers, rating agencies, and public institutions, use EDW's data for monitoring, comparison, and risk assessment purposes.
For more information about European DataWarehouse, visit: www.eurodw.eu.
About Zenith Global S.p.A.
Zenith Global is a financial intermediary specialising in the management of structured finance operations. Founded in 2000, with a "Strong" rating from S&P Global Ratings, Zenith Global manages over 250 securitisation vehicles (SPVs) and over €48 billion in performing, UTP (unlikely to pay), NPL, and real estate assets in the role of Master Servicer under the Italian Securitisation Law (130/99).
For more information about Zenith Global, visit: www.zenithglobal.eu.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241014680446/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom